Freddy Yip

Cooley advised ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate therapeutics for patients with cancer, on its definitive agreement to be acquired for $1.8 billion in an all-cash transaction by Genmab (NASDAQ: GMAB), a dual-listed, international biotechnology company that creates and develops differentiated antibody therapeutics to fight against cancer and other serious diseases.

Cooley advised IASO Biotherapeutics, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, on its new set of collaborations with Umoja Biopharma for the development and commercialization of novel ex vivo and in vivo cell and gene therapies.

Cooley advised SystImmune, a clinical-stage biopharmaceutical company, on its exclusive license and collaboration agreement with Bristol Myers Squibb for SystImmune’s BL-B01D1.

Cooley advised Jiangsu Hengrui Pharmaceuticals, a leading global pharmaceutical company headquartered in China with a focus on research, development, manufacturing and commercialization of innovative and high-quality healthcare products, on its strategic collaboration and exclusive worldwide (excluding mainland China) license agreement with Merck KGaA, Darmstadt, Germany and global license agreement (excluding the Greater China region and Korea) with Elevar Therapeutics.

Cooley advised Immatics, a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, on its strategic collaboration with Moderna.